BIVI News and Press, BioVie Inc. From 06/23/23

2023-06-23 08:10:16 ET Drug therapies company BioVie ( NASDAQ: BIVI ) said on Friday that it is set to join the U.S. small-cap Russell 2000 and Russell 3000 indexes. The addition is effective after June 26 market open. BIVI shares were trading +3.42% pre-market. So...

CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...

CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...

--News Direct-- BioVie chief medical officer Dr Joseph Palumbo joins Natalie Stoberman from the Proactive newsroom to share the company's latest research and social impact on cognitive diseases to bring awareness to Alzheimer's & Brain Awareness Month. Palumbo says BioVie's latest...

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 5.36% on the day to $6.1. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its prod...

2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -9.65% on the day to $5.67. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -5.53% on the day to $6.24. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...

BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.86% on the day to $7.05. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pro...

CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,&...